M13A
Bioequivalence for Immediate-Release Solid Oral Dosage Forms
Current edition
Step 4, 23 July 2024
Current edition
Step 4, 23 July 2024
About this standard
Gives recommendations for bioequivalence studies of immediate-release solid oral dosage forms such as tablets and capsules, during development and after approval. It does not cover how regulators decide based on the results.
Recognition by market
Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts
- European UnionImplemented
- Edition accepted
- -
- National code
- EMA/CHMP/ICH/953493/2022
Effective January 25, 2025
- South KoreaNot yet implemented
- Edition accepted
- -
- National code
- -
Implementation is in progress. Date listed: 31 December 2026.
- SwitzerlandImplemented
- Edition accepted
- -
- National code
- -
Effective July 23, 2024. ICH guidelines apply in Switzerland automatically once they reach Step 4.
Testing requirements that cite it
Open the market page and its pathway pages for the full requirement, protocol and report content
United States
- Bioequivalence studies with pharmacokinetic endpoints for generic drugsBioequivalence · Not stated
European Union
- Bioequivalence studies for immediate-release oral generics (ICH M13A with the EMA guideline)Bioequivalence · Not stated
United Kingdom
- Bioequivalence: ICH guidelines implemented by the MHRABioequivalence · Not stated
Canada
- Bioequivalence acceptance limits, critical dose and highly variable drugsBioequivalence · Not stated
- Design and conduct of comparative bioavailability and bioequivalence studiesBioequivalence · Not stated
Switzerland
- Bioequivalence and comparative bioavailability studies for known active substancesBioequivalence · Not stated
- Biowaivers and strengths to be examinedBioequivalence · Not stated
Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9. See all standards.